Logos Global Management LP
Long book
$1.94B
Q1 2026
Positions
63
Top-10 weight
51%
concentration
Last quarter
+23.9%
SPY +14.8%
Turnover
33%
of book per quarter
Strategy in plain words
auto-generated from filingsLogos Global Management LP is a concentrated fundamental stock-picker, specialised in healthcare (99% of the long book), running a $1.94B US long book across 63 positions.
The portfolio is concentrated: the top 10 names carry 51% of the portfolio. The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: REVOLUTION MEDICINES INC, ERASCA INC, IDEAYA BIOSCIENCES INC, PRAXIS PRECISION MEDICINES I, CENTESSA PHARMACEUTICALS-ADR.
Over the last 9 quarters its long book ran on average 3.8pp per quarter ahead of the S&P 500, beating the index in 5 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-12.8%
Q2 2024
+8.8%
Q3 2024
-11.7%
Q4 2024
-28.9%
Q1 2025
+7.2%
Q2 2025
+30.6%
Q3 2025
+40.5%
Q4 2025
+17.0%
Q1 2026
+23.9%
Sector allocation
Healthcare 94%
Other 5%
Materials 1%
Long book by quarter
What does Logos Global own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| RVMD REVOLUTION MEDICINES INC | Healthcare | 2.0M | $194.5M | 10.0% | Held |
| ERAS ERASCA INC | Healthcare | 11.2M | $180.4M | 9.3% | -14.2% |
| IDYA IDEAYA BIOSCIENCES INC | Healthcare | 3.5M | $115.0M | 5.9% | +10.4% |
| PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 285.0K | $91.8M | 4.7% | -24.0% |
| 430 TERNS PHARMACEUTICALS INC | — | 1.5M | $79.1M | 4.1% | +100.0% |
| TNGX TANGO THERAPEUTICS INC | Healthcare | 3.0M | $62.8M | 3.2% | -28.6% |
| CYTK CYTOKINETICS INC | Healthcare | 875.0K | $57.7M | 3.0% | +191.7% |
| OLMA OLEMA PHARMACEUTICALS INC | Healthcare | 3.2M | $47.8M | 2.5% | Held |
| UTHR UNITED THERAPEUTICS CORP | Healthcare | 80.0K | $47.4M | 2.4% | New |
| MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 85.0K | $44.5M | 2.3% | New |
| RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 450.0K | $39.1M | 2.0% | +136.8% |
| CGON CG ONCOLOGY INC | Healthcare | 575.0K | $38.9M | 2.0% | +187.5% |
| MAZE MAZE THERAPEUTICS INC | Healthcare | 1.2M | $36.9M | 1.9% | +30.0% |
| BIIB BIOGEN INC | Healthcare | 200.0K | $36.7M | 1.9% | Held |
| IRON DISC MEDICINE INC | Healthcare | 560.0K | $35.8M | 1.8% | +9.8% |
| DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 400.0K | $33.6M | 1.7% | +27.0% |
| OCUL OCULAR THERAPEUTIX INC | Healthcare | 3.9M | $32.6M | 1.7% | +10.0% |
| TYRA TYRA BIOSCIENCES INC | Healthcare | 850.0K | $32.6M | 1.7% | +304.8% |
| TRVI TREVI THERAPEUTICS INC | Healthcare | 2.4M | $28.6M | 1.5% | +54.8% |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 1.5M | $28.0M | 1.4% | -14.3% |
| IMVT IMMUNOVANT INC | Healthcare | 1.1M | $26.7M | 1.4% | -21.8% |
| XENE XENON PHARMACEUTICALS INC | Healthcare | 450.0K | $26.2M | 1.3% | New |
| RCUS ARCUS BIOSCIENCES INC | Healthcare | 1.2M | $25.9M | 1.3% | New |
| DYN DYNE THERAPEUTICS INC | Healthcare | 1.4M | $25.4M | 1.3% | +12.0% |
| LBRX LB PHARMACEUTICALS INC | Healthcare | 915.0K | $22.6M | 1.2% | -23.8% |
| ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 540.0K | $21.2M | 1.1% | +58.8% |
| DSGN DESIGN THERAPEUTICS INC | Healthcare | 1.9M | $20.7M | 1.1% | -22.0% |
| NERV MINERVA NEUROSCIENCES INC | Healthcare | 3.2M | $19.4M | 1.0% | -2.9% |
| NAMS NEWAMSTERDAM PHARMA CO NV | Healthcare | 600.0K | $19.2M | 1.0% | +33.3% |
| MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 200.0K | $18.5M | 1.0% | -11.1% |
| PCVX VAXCYTE INC | Healthcare | 300.0K | $17.4M | 0.9% | -53.8% |
| ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 750.0K | $16.7M | 0.9% | -11.8% |
| CMPX COMPASS THERAPEUTICS INC | Healthcare | 3.1M | $16.7M | 0.9% | +173.9% |
| CLDX CELLDEX THERAPEUTICS INC | Materials | 450.0K | $14.3M | 0.7% | +28.6% |
| JANX JANUX THERAPEUTICS INC | Healthcare | 1.0M | $13.9M | 0.7% | Held |
| VOR VOR BIOPHARMA INC | Healthcare | 750.0K | $13.4M | 0.7% | +650.0% |
| ALKS ALKERMES PLC | Healthcare | 350.0K | $12.4M | 0.6% | New |
| ORIC ORIC PHARMACEUTICALS INC | Healthcare | 950.0K | $12.0M | 0.6% | +111.1% |
| IMMX IMMIX BIOPHARMA INC | Healthcare | 1.2M | $11.2M | 0.6% | +22.5% |
| TENX TENAX THERAPEUTICS INC | Healthcare | 625.0K | $10.0M | 0.5% | New |
| AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 700.0K | $9.7M | 0.5% | -26.3% |
| CBIO CRESCENT BIOPHARMA INC | Healthcare | 482.5K | $8.9M | 0.5% | -19.6% |
| SLNOEUR SOLENO THERAPEUTICS INC | — | 250.0K | $8.4M | 0.4% | -16.7% |
| AVBP ARRIVENT BIOPHARMA INC | Healthcare | 350.0K | $8.1M | 0.4% | New |
| RLAY RELAY THERAPEUTICS INC | Healthcare | 750.0K | $7.5M | 0.4% | New |
| CRVS CORVUS PHARMACEUTICALS INC | Healthcare | 450.0K | $6.6M | 0.3% | -10.0% |
| MGTX MEIRAGTX HOLDINGS PLC | Healthcare | 700.0K | $6.1M | 0.3% | New |
| JBIO JADE BIOSCIENCES INC | Healthcare | 400.0K | $5.6M | 0.3% | +1.3% |
| VSTM VERASTEM INC | Healthcare | 1.0M | $5.3M | 0.3% | -41.2% |
| AVTX AVALO THERAPEUTICS INC | Healthcare | 300.0K | $4.5M | 0.2% | New |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 66 | $2.00B | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 69 | $1.65B | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 59 | $1.12B | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 51 | $903.8M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 39 | $562.5M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 47 | $854.6M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 55 | $926.8M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR/ANEW HOLDINGS | Aug 27, 2024 | 57 | $1.24B | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 54 | $1.23B | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 57 | $1.24B | canonical | SEC ↗ |